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To the Editor: Lassa fever affects 
≈100,000 persons per year in West Af-
rica (1). The disease is caused by Las-
sa virus, an arenavirus, and is associ-
ated with bleeding and organ failure. 
The case-fatality rate in hospitalized 
patients is 10%–20%. The reservoir 
of the virus is multimammate mice 
(Mastomys natalensis). Investigations 
in the 1970s and 1980s pointed to the 
existence of 3 disease-endemic zones 
within Nigeria: the northeastern re-
gion around Lassa, the central region 
around Jos, and the southern region 
around Onitsha (2,3). The current 
epidemiologic situation is less clear 
because no surveillance system is in 
place. 
In 2003 and 2004, we conducted a 
hospital-based survey in Irrua, which 
demonstrated ongoing transmission 
of the virus in Edo State, Nigeria (4). 
Since then, laboratory capacity at the 
University of Lagos for diagnosing 
Lassa fever has been improved and 
used for small-scale passive surveil-
lance in other parts of the country. 
Public health offi cials or hospital 
staff reported suspected cases. Blood 
samples were sent to Lagos, or staff 
from Lagos collected samples on site. 
Confi rmatory testing, sequencing, and 
virus isolation were performed at the 
Bernhard Nocht Institute for Tropi-
cal Medicine in Hamburg, Germany. 
Primary testing was done by reverse 
transcription–PCR (RT-PCR) that 
targeted the glycoprotein (GP) gene 
(5,6). An RT-PCR that targeted the 
large (L) gene was used as a second-
ary test (7), and PCR products were 
sequenced. Serologic testing for Lassa 
virus–specifi c immunoglobulin (Ig) 
G and IgM was performed by immu-
nofl uorescent antibody test using Vero 
cells infected with Lassa virus. Virus 
isolation with Vero cells was conduct-
ed in the BioSafety Level 4 laboratory 
in Hamburg.
From 2005 through 2008, 10 cases 
of Lassa fever were confi rmed by vi-
rus detection (cases 3–10) or implicat-
ed by epidemiologic investigation and 
serologic testing (cases 1 and 2) (on-
line Appendix Table, www.cdc.gov/
EID/content/16/6/1040-appT.htm). 
Case-patients 1–4 were involved in 
a nosocomial outbreak that occurred 
in February 2005 at the Ebonyi State 
University Teaching Hospital (EB-
SUTH) in Abakaliki. Retrospective 
investigation suggests the following 
transmission chain. The presumed 
index case-patient was a male nurse 
living in Onitsha, who became ill on 
January 21, 2005, and traveled ≈200 
km to EBSUTH for better medical 
treatment. The detection of Lassa vi-
rus–specifi c IgM during his convales-
cent phase indicates that he had Lassa 
fever. The second case-patient was a 
female nurse who had contact with 
the index case-patient on February 4. 
She was admitted on February 7 and 
died 6 days later. Her clinical features 
were compatible with Lassa fever, but 
laboratory confi rmation is lacking be-
cause specimens were not collected. 
Two additional case-patients among 
hospital staff (case-patients 3 and 4) 
were seen on February 21; each had 
had contact with case-patient 2. Case-
patient 3 took care of case-patient 2 
and slept in the same room with her 
for 4 days. Lassa fever was confi rmed 
in case-patients 3 and 4 by RT-PCR 
as well as by IgM and IgG serocon-
version in the surviving patient (case-
patient 3). Case-patient 4, a pregnant 
nurse, had a spontaneous abortion and 
died on day 9 of hospitalization. Se-
quencing the GP and L gene PCR frag-
ments showed that case-patients 3 and 
4 were infected with the same virus 
strain (100% identity). In March and 
April 2005, blood was collected from 
50 hospital staff members (including 
those who had had contact with the 
case-patients) and screened for Lassa 
virus–specifi c IgM and IgG. No posi-
tive blood samples were found, which 
indicated that no additional staff mem-
bers were involved in the outbreak.
Case-patients 5 and 6 were admit-
ted to EBSUTH in 2008 on January 17 
and March 5, respectively. Both were 
medical doctors, one at a local hospi-
tal and the other at EBSUTH, and both 
died. Encephalopathy with general-
ized seizures and loss of conscious-
ness preceded death in both cases. 
The source of infection is unknown, 
although it is likely that they became 
infected while they treated patients 
without knowing they had Lassa fever. 
In agreement with the epidemiology, 
the viruses from the 2 patients were 
similar, though not identical (89% and 
87% identity in the GP and L genes, 
respectively).
Cases 7 to 10 occurred in Abuja 
and Jos from December 2007 through 
March 2008. Healthcare workers ap-
peared not to be involved, and no 
molecular epidemiologic evidence 
indicated that transmission occurred 
among the 3 case-patients from Jos 
(94–97% and 90–94% identity in the 
GP and L genes, respectively).
In conjunction with our previ-
ous report (4), the cases presented 
here demonstrate current Lassa fever 
activity in the states of Edo, Ebonyi, 
Federal Capital Territory, and Plateau. 
These fi ndings correspond to early re-
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ports on Lassa fever in southern and 
central parts of Nigeria. That health-
care workers are still at as high a risk 
of contracting and dying from the dis-
ease as they were 20 years ago (8) is 
alarming. 
A key to solving this problem 
would be the establishment of diag-
nostic facilities that can provide rapid 
molecular testing at referral centers in 
the disease-endemic zones. This test-
ing would facilitate appropriate case 
and contact management, including 
early treatment and postexposure pro-
phylaxis with ribavirin, and eventu-
ally raise awareness that Lassa fever 
should be considered in every severe 
febrile illness in these regions.
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Laboratory 
Diagnosis of Lassa 
Fever, Liberia 
To the Editor: Lassa fever is en-
demic in West Africa, with <300,000 
Lassa virus (LASV) infections oc-
curring annually (1). Persons on hu-
manitarian missions and peacekeeping 
forces in regions comprising Sierra 
Leone and Liberia are at risk for Lassa 
fever (2–4). Reliable laboratory diag-
nosis, particularly in acute cases, is 
crucial for triage, implementation of 
barrier nursing, and contact tracing, as 
well as for initiation of treatment with 
ribavirin. Reverse transcription–PCR 
(RT-PCR) is routinely used for confi r-
mation of cases, but few proven assay 
formulations are available, and these 
have not been evaluated on larger co-
horts of patients (5).
We summarize our experiences 
from testing 184 patients from Libe-
ria with suspected cases of Lassa fever 
with the most widely used LASV-spe-
cifi c RT-PCR assay (6). Patients were 
suspected of having Lassa fever on 
clinical grounds by physicians of the 
United Nations peacekeeping troops 
and other international relief organiza-
tions. Patients included local citizens 
as well as members of the mentioned 
organizations. EDTA-plasma samples 
or serum specimens packed on ice 
were sent to our laboratory in Ham-
burg, Germany, by international air-
freight, taking 4–7 days for shipment. 
Information on clinical signs and 
symptoms or outcome was generally 
not available.
Conventional RT-PCR specifi c for 
the glycoprotein precursor gene was 
conducted as described (7). RT-PCR 
results positive for LASV was seen 
in 35 (19%) of 184 patients. Median 
time between onset of symptoms and 
sampling was 7 days. Median time 
from reception of samples to fi nal RT-
PCR or culture results was 1 day and 4 
days, respectively.
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